Long-term consequences of treating postnatal depression with selective serotonin reuptake inhibitors: Exploring effects on mother and child

Chao-Yu Liu, MD, PhD [1], Eivind Ystrom, PhD [2,3,4], Tom A. McAdams, PhD [1,2]

1 Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK
2 PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway
3 Department Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway
4 Pharmaco-Epidemiology and Drug Safety Research Group, School of Pharmacy, University of Oslo, Oslo, Norway

* *Address for correspondence:
Dr Chaoyu Liu,
Social, Genetic and Developmental Psychiatry Centre, King's College,
16 De Crespigny Park
London SE5 8AF
Telephone +44 (0)20 7848 0859
Email: kate.liu@kcl.ac.uk

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

Running title: long-term consequences of treating postnatal depression with SSRI

Key words: postnatal depression; long-term effect; antidepressants; SSRI; externalizing behavior; development

Word count: 4334

Abstract

Background

Although selective serotonin reuptake inhibitors (SSRIs) are a recommended intervention for postnatal depression (PND), a lack of evidence regarding the long-term consequences of postnatal SSRI use have resulted in treatment hesitancy.

Methods

Longitudinal data on a total of 54576 mother-child dyads enrolled in the Norwegian Mother and Child Cohort Study (MoBa) were examined. We used multilevel models to test associations between PND and maternal outcomes (depression and anxiety, relationship satisfaction) and child outcomes (motor and language development, emotional and behavioral problems) from birth to postpartum year 5. We included an interaction term in models to test whether postnatal SSRI treatment moderated the effects of PND. We used a propensity score to control for pre-/antenatal factors that impacted the probability of receiving SSRIs.

Results

PND was associated with poor maternal mental health outcomes and problems in child emotional and behavioral development. Use of SSRIs mitigated the associations between PND and later maternal depression and child externalizing behaviors up to postpartum year 5. We found no evidence to indicate that postnatal exposure to SSRIs was associated with increased risk of any negative outcomes in women or their offspring.

Conclusions

SSRIs bring benefits in the long term by attenuating the detrimental associations between PND and subsequent maternal depression and child externalizing behaviors. Our findings provide valuable information for clinicians and women with PND to consider when making decisions regarding treatment.

Introduction

Postnatal depression (PND) is a common psychiatric disorder that affects 10 to 15% of women in the first year after childbirth [1]. Depression is among the most influential illnesses on global burden of mortality and disability [2]. The clinical presentation of PND resembles that of major depressive disorder, which is characterized by impairing symptoms of depressed mood, lack of interest, fatigue, poor concentration, and suicidal thoughts [3]. In addition to depression during the postpartum period, women affected by PND are more susceptible to recurrent depressive episodes in subsequent pregnancies and display higher levels of depression and anxiety in the years following childbirth [4, 5]. It is noteworthy that PND also predicts adverse outcomes in the wider family. PND is associated with long-term partner relationship problems [6] which, in turn, is a risk factor for perinatal depression and prolonged PND courses in affected women [7-9]. Children born to mothers with PND also show increased difficulties in social adaptation, delayed cognitive development, and higher levels of behavioral and emotional problems [10, 11]. Moreover, persistent PND symptoms further the risk to child's development, whilst remittance of PND is associated with normalization of behavioral problems and psychopathology of the affected children [12, 13]. Such findings suggest that effective intervention for PND may mitigate some of the negative consequences associated with the condition.

The effectiveness of antidepressants in the management of PND has been proven by meta-analysis of data from randomized control trials [14]. Selective serotonin reuptake inhibitors (SSRIs) are often the medication of choice to treat PND due to better safety profiles and tolerance compared to other antidepressants such as tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOi) [15]. However, there is insufficient evidence

regarding the long-term consequences of postnatal SSRI use for women and their children [14]. Findings regarding associations between *ante*natal exposure to SSRIs and delay in motor and language development and increased emotional problems of children raise concerns about neurodevelopmental consequences associated with postnatal SSRI exposure [16-19]. In addition, although studies have pointed out that SSRIs recommended in the treatment for PND produce undetectable to very low serum levels in the exposed infants [20, 21], data on longitudinal neurodevelopmental effects are lacking [14]. Insufficient evidence on safety for children may lead to hesitancy towards pharmacological treatment in affected women, which potentially increases the risks of poorly controlled PND symptoms, a prolonged disease course, and more functional impairment [22].

In the current study we set out to examine the risks and benefits associated with postnatal SSRI use in the management of PND. Using data collected from pregnancy to postpartum year 5, we examined short- and long-term maternal mental health outcomes, alongside child developmental outcomes associated with PND. We then explored whether SSRI treatment moderated associations between PND and the study outcomes. It is noteworthy that several personal and environmental factors may influence treatment for PND, the use of SSRIs and associated outcomes. For example, women with more severe PND symptoms, lifetime depression diagnosis and prior experience with pharmacological intervention for depression are more likely to receive SSRIs for PND [22, 23]. The aforementioned factors, such as higher levels of perinatal depression and anxiety and history of depression have also been linked to increased risk of PND and poorer maternal and child outcomes [13, 24]. Therefore, to avoid spurious conclusions being drawn regarding associations between SSRIs and negative maternal and child outcomes, a careful control for potential sources of confounding is crucial. To control for confounding factors that might partially or completely explain

associations between PND and/or SSRI use and our outcomes, we included a propensity score derived from prenatal and antenatal variables that differentiated PND and/or treatment status as a covariate to adjust for probability of postnatal SSRI exposure.

Based on available data on infant's response to the use of SSRI [25] and the positive outlook associated with well managed PND [26], we hypothesized that SSRI treatment can bring more benefits than harm in the long term for affected women, their children, and family.

Methods

Sample

Data were obtained from the Norwegian Mother and Child Cohort Study (MoBa), a prospective population-based cohort study in Norway. MoBa recruited women who attended routine ultrasound examination in week 17-18 of pregnancy from year 1999 to 2008. Women were invited to participate multiple times when they had more than one pregnancy. Among 277,702 invitations sent, over 95,000 women and 114,000 children were enrolled (participation rate of 41%) [27]. Participating families received questionnaires for child development and maternal health conditions across several assessments from gestational week 17 till present. All the participants also have records linked with the Medical Birth Registry of Norway (MBRN), which registers pregnancy outcomes in Norway after the 12th gestational week and other national registry database. This study is based on version 12 of the quality-assured data release in January 2019. The current study included women with data on their depression symptoms at gestation week 30 and postpartum month 6, and data on self-reported medication use for mental health problems at postpartum month 6. To maximize our study sample, we included all pregnancies and randomly selected 1 child from each twin birth.

Measurement

Postnatal Depression (PND)

PND symptoms were measured using 6 items from the Edinburgh Postnatal Depression Scale (EPDS) [28] at postpartum month 6. The sum of the 6-item version has been shown to correlate highly (r=0.961) with the 10-item full version of the EPDS. Cronbach's alpha for the 6-item EPDS was 0.84 in the MoBa sample. In addition to the EPDS, women were asked if they had experienced any postnatal mental health problems at postpartum month 6. This was part of a series of questions regarding health problems/illnesses experienced during pregnancy and since the birth. In the present study we defined women as experiencing postnatal depression (PND) if the mother reported that she had experienced mental health problems *and* scored above the 50th percentile score of the EPDS at postpartum month 6. PND status was coded separately for each pregnancy.

Non-treated PND dyads and treated PND dyads

Women were asked to report any medications they had taken as treatment if they reported mental health problems at postpartum month 6. The reported medication was identified using the Anatomic Therapeutic Classification (ATC) system of the World Health Organization. Because SSRIs are the most prescribed and researched antidepressants for perinatal mental health problems [14] and are recommended as the first-line treatment by multiple treatment guidelines [15, 29], the current study focused exclusively on the use of SSRIs. Women with PND who reported treatment with only anxiolytics (ATC class N05B), hypnotics (ATC class N05C) or non-SSRI antidepressants (ATC class N06AA, N06AF, N06AX) were excluded from analyses (n=84). If mothers identified as having PND reported SSRI (with ATC class

N06AB) use, they were classified as a 'treated PND case'. Conversely, if the mother did not report SSRI use, she was classified as a 'non-treated PND case'.

Three mutually exclusive groups of mother-child dyads were identified: non-PND (n=52516), non-treated PND (n=1877) and treated PND (n=183). Due to the small number of participants who reported SSRI use, analyses comparing individual SSRIs were not performed.

Prenatal and antenatal factors – potential confounding variables

Prenatal maternal factors included self-reported current and/or lifetime depression history, educational level and income at gestation week 17. Educational level was reported on a scale of 1 to 6, with 1 indicating 'secondary school' and 6 'higher education (university and above)'. Income was yearly gross income of the mothers, from 1 as 'no income' to 7 as 'over 500.000 NOK'.

Antenatal factors included alcohol and tobacco consumption during pregnancy, maternal age at childbirth, parity and maternal depression and anxiety. Antenatal alcohol consumption was collected at gestational week 30. We categorized the response to 'ever use' alcohol if the women reported alcohol consumption across any of the three trimesters during pregnancy. 'Ever use' tobacco was defined as tobacco smoking during the last three months of pregnancy reported at postpartum month 6. Antenatal maternal depression and anxiety were assessed with the 8-item short version of the Hopkins Symptom Checklist (SCL-8) [30] at gestational week 30. The SCL-8 can be divided into subscales for depression and anxiety, with 4 items in each. The SCL-8 correlates well with the depression and anxiety scores of the original instrument and has Cronbach's alpha of 0.78 and 0.82 for the anxiety and depression subscales respectively [31].

Maternal outcomes

Maternal outcomes included maternal depression and anxiety and partner relationship satisfaction after childbirth. Maternal depression and anxiety were assessed with the SCL-8 at postpartum years 1.5, 3 and 5.

Relationship satisfaction was assessed via maternal report on the 5-item short version Relationship Satisfaction Scale (RSS) at postpartum month 6, years 1.5 and 3. Items were rated on a 6-point scale to reflect marital satisfaction (e.g. 'I am very happy with our relationship') and partner relationship quality (e.g. 'my partner is generally understanding'). The RSS demonstrates good psychometric properties [32] and shows high predictive validity of overall life satisfaction [33].

Child outcomes

Child outcomes comprised maternal reports on child internalizing and externalizing behaviors, ADHD symptoms and motor and language development. Internalizing and externalizing behaviors were measured with selected items from the Child Behavior Checklist (CBCL) [34] at ages 1.5, 3 and 5 years. There were in total 3 items for internalizing behaviors and 8 items for externalizing behaviors overlapping across the three time points. Composite scores for internalizing and externalizing behaviors were calculated separately at each time point. Higher scores suggested more severe problems.

ADHD symptoms were assessed with items from the Conners Parent Rating Scale-Revised, Short Form (CPRS-R) [35] when the child was 5 years old. We calculated a composite score from the 12 available items of the CPRS-R tapping inattention and hyperactivity/impulsivity in the MoBA questionnaire to indicate ADHD symptom level.

Motor and language development were measured with items from the Ages and Stages Questionnaire (ASQ) [36] when the child was 1.5 and 3 years old. The Norwegian version of the ASQ has shown high agreement (84%) with standardized assessment tests and effective predictive validity for children with developmental delay [37]. Composite scores for motor and language development were calculated for ages 1.5 and 3 years respectively, with higher scores suggesting better performance.

Data Analysis

Analyses were conducted with R (R version 4.0.3)[38]. We used the False Discovery Rate (FDR) approach at FDR<5% to adjust for multiple testing [39].

Prenatal and antenatal factors associated with PND and SSRI treatment: creating a propensity score to adjust for potential confounding

We compared prenatal and antenatal factors between non-PND and PND dyads and between treated- and non-treated PND dyads. Logistic regressions for each factor and multiple logistic regressions including all variables were used to identify factors differentiating PND dyads and SSRI use. Factors that differentiated PND dyads in multiple regression were treated as potential sources of confounding and were used to generate a propensity score to adjust for SSRI exposure probability for each pregnancy. Because the low numbers of SSRI users result in limited power to identify predictors of SSRI use and factors associated with SSRI use and PND often overlap [40, 41], we included variables that differentiated PND dyads from non-PND controls as well as variables that differentiated SSRI-treated dyads from non-treated dyads for more comprehensive control. This propensity score was included in the following analyses as a covariate to control for potential confounding in the associations between PND, SSRI treatment and study outcomes.

Effects of PND on maternal and child outcomes and the moderation of SSRI

To study associations between PND and maternal and child outcomes, we ran multilevel models with random intercepts (R package 'lcmm') [42] at the maternal level to account for non-independence in our study sample (multiple pregnancies nested within mothers). The models were then expanded to include covariates (child sex, birthweight, maternal age, education, income, parity, maternal lifetime depression diagnosis, antenatal depression and anxiety and the propensity score). Finally, we included the interaction between SSRI and PND in the multivariable models to examine whether receiving SSRI moderated the associations between PND and study outcomes.

Results

Prenatal and antenatal factors predicting PND and SSRI treatment

Descriptive statistics for prenatal and antenatal factors are presented in Table 1.1 and Table 1.2. Pairwise comparison showed that compared with non-PND women, women with PND were younger, had lower parity, lower educational levels and lower income (Table 1.1). They also reported more alcohol and tobacco use during pregnancy, elevated levels of depression and anxiety before childbirth, and a higher proportion reported a lifetime history of depression diagnoses. Multivariable logistic regression including all the variables showed that lower parity (OR 0.91, 95%CI 0.86,0.97), lower income (OR 0.87, 95%CI 0.83,0.92), more alcohol use during pregnancy (OR 1.06, 95%CI 1.01,1.11), lifetime history of depression (OR 4.70, 95%CI 4.19,5.27), higher levels of antenatal depression (OR 1.45, 95%CI 1.38,1.52) and anxiety (OR 1.35, 95%CI 1.29,1.41) differentiated PND women from non-PND controls. Fewer factors differentiated treated and non-treated PND women (Table 1.2). Women in the treated PND group reported a lower educational level (OR 0.84, 95%CI

0.71,1.00) and more of them reported a lifetime history of depression (OR 3.08, 95%CI 2.20,4.32). Although differences in antenatal depression and anxiety levels were observed between treated and non-treated dyads, they failed to differentiate SSRI treatment status in the multivariable model (antenatal depression OR 0.95, 95%CI 0.82, 1.09; antenatal anxiety OR 1.14, 95%CI 1.00, 1.29). Factors differentiating PND status and treatment status were used to generate a propensity score. The included factors were parity, maternal education, income, lifetime depression history, antenatal alcohol consumption, antenatal depression and anxiety level and the EPDS score at postnatal month 6.

The association between PND, SSRI treatment and maternal and child outcomes in non-PND dyads and PND dyads

Maternal and child outcomes in non-PND dyads and PND dyads are shown in *Table 2*. Table 2 also presents crude beta estimates from univariable regressions using PND as the predictor variable, adjusted beta estimates from multiple regressions with covariates, and estimates from models with PND*SSRI moderation terms. Univariable analyses showed that PND was associated with higher levels of depression and anxiety across postpartum year 1.5 to year 5, and poorer relationship satisfaction across postpartum month 6 to year 3. PND was associated with higher levels of child internalizing and externalizing behaviors measured across ages 1.5 to 5 years, elevated ADHD symptoms at age 5 and poorer motor and language development at years 1.5 and 3. Most associations remained significant, if somewhat attenuated, after adjustment for covariates (the exception being that between PND and child internalizing behaviors at 1.5 years).

Moderation effects of SSRI treatment on the relationships between PND and maternal and child outcomes

SSRI treatment significantly reduced the negative impact of PND on the following maternal outcomes (see Table 2 for full details): maternal depression at postpartum year 1.5 and postpartum year 5, maternal anxiety at postpartum year 1.5 and relationship satisfaction at postpartum month 6, years 1.5 and 3.

SSRI treatment also significantly reduced the associations between PND and the following child outcomes: externalizing behaviors at ages 1.5 and 5 years, and ADHD symptoms at age 5 years. There was no evidence that SSRI treatment moderated the associations between PND and child internalizing behaviors, or motor and language development across the 5-year follow up. The direction of effects for all interaction terms (significant and non-significant) except for maternal anxiety at postpartum year 3 indicated that maternal SSRI use did not or very unlikely to worsen associations between PND and any of our outcomes.

Discussion

We used data from a population-based cohort to study long-term outcomes for mother-child dyads affected by postnatal depression (PND) and provide insights into whether SSRI use moderated any observed relationships. We found that women who received SSRIs for PND showed comparable postnatal depression severity with their non-treated counterparts but were more likely to have a prior history of depression. PND was associated with poorer maternal and child outcomes up to 5 years postpartum. Our analyses indicated that treatment with SSRIs attenuated the detrimental associations between PND and subsequent maternal depression and child externalizing behaviors. Overall, we found no evidence to suggest that SSRIs conferred an increased risk for any of the study outcomes.

Prenatal and antenatal factors differentiated PND and SSRI treatment

When different prenatal and antenatal factors were examined together, a lifetime depression diagnosis was associated with the highest risk for PND, followed by higher levels of antenatal depression and anxiety. These findings are in line with meta-synthesised data indicating that depression and anxiety during pregnancy and a previous history of depression conferred the largest risks of PND, greater than factors such as pregnancy related complications, maternal neuroticism, and socioeconomic adversity [41]. It is noteworthy that the strong risk (4.7 times increased) associated with a lifetime diagnosis of depression in the development of PND was observed independently of the levels of antenatal depression and anxiety in the current study. Such findings are consistent with the knowledge that recurrent mood episodes during the postpartum period are common in women with pre-existing major depression [43]. More importantly, it suggests that prenatal screening for maternal mental health history can be useful in signposting a heightened risk of PND.

Interestingly, only a previous history of depression predicted SSRI use. Ante- and postpartum depression levels did not differentiate the treated and non-treated women. This suggests that depression severity may not be the strongest determinant of the use of SSRIs for PND in our sample. Indeed, information gathered from health professionals and women with PND suggests that the lack of awareness of mental health problems (e.g. viewing postnatal depression as a maladaptive psychosocial adjustment to motherhood) and higher socioeconomic status (e.g. having money or resources for more specialised treatment services) are negatively associated with antidepressant use for postnatal depressive symptoms [23, 44, 45]. Although reflection on the mechanism that leads to the use of SSRIs for PND remains speculative, our findings suggest that women with a history of depression may be more aware

of their mental health conditions and thus more open to the idea of pharmacological intervention. Such views had been documented among women with PND or treated for PND in prior research [22, 46].

PND and maternal and child outcomes

In our cohort, PND predicts elevated levels of postnatal maternal depression, anxiety, and relationship dissatisfaction up until 5 years after childbirth. Postnatal maternal anxiety has been associated with a range of negative developmental effects in children, including impaired socio-emotional development and increased externalizing behaviours [47, 48]. Partner relationship dissatisfaction is an established risk factor for marital conflict, increased psychological distress among family members, and poor parental involvement in childcare [7, 49]. It is noteworthy that relationship dissatisfaction also predicts the increase and persistence of PND symptoms [50]. These findings echo previous studies in suggesting that harmful consequences associated with PND can be found not only in affected women but also in the wider family [5, 12]. Our findings on the associations between PND and child outcomes are in line with related research which shows that children of mothers with PND are at risk of behavioral problems and developmental delay [26]. Crucially, our study and others have identified links between PND and long-term impairment of cognitive, emotional and behavioral functioning in exposed children [13, 51, 52]. The findings highlight the importance of early intervention for PND to prevent unfavorable outcomes in offspring in the long term.

Moderation of SSRI treatment on the relationship between PND and postnatal outcomes

Considering the negative associations PND has with a wide range of outcomes, adequate treatment for PND is crucial. However, limited evidence on the long-term consequences

associated with antidepressant use during postpartum period in children has led to treatment hesitancy in women with PND [22]. The dilemma regarding whether to label depression during the postnatal period a psychiatric condition, combined with uncertainty regarding the safety of postnatal antidepressant use, also affects clinical judgement and the management of PND among health professionals [53]. The current study used longitudinal data on a large mother-child cohort to investigate benefits and risks associated with SSRI treatment for PND. We found that SSRI treatment mitigated the effects of PND on subsequent maternal depression and relationship dissatisfaction. That the positive effects of SSRI treatment were observed up to 5 years after childbirth further indicates that SSRI treatment reduces the risk of depression persistence and is beneficial to the family environment in the long term. Our study also identified that SSRI use mitigated the negative associations between PND and negative child outcomes. Specifically, our results suggest that SSRI treatment can negate the negative associations between PND and externalizing behaviors across early childhood and ADHD symptoms at age 5 years. The findings add to the knowledge that adequate treatment for PND can normalize child behavioral problems associated with the condition [54]. As for the concern that adverse child outcomes may be associated with postnatal SSRI exposure, we found no evidence that SSRIs conferred an increased risk of problems in emotion, behavior, motor or language domains up to 5 years of age.

Limitations

A major strength of our study is the longitudinal design with repeated measurement in a large mother-child cohort. Our findings fill a gap in the literature in providing data on long-term child outcomes associated with SSRI use for PND. As hypothesized, evidence shows that

SSRI treatment brings benefits to affected women and their family in the long term. Our study did not identify harm associated with postnatal SSRI use.

Notwithstanding the strengths, several limitations warrant mention. First, all variables were assessed via maternal self-report. Previous research indicates that larger discrepancies in reporting of child emotional and behavioral problems between mother-child dyads were observed among depressed women and their children[55]. It is possible that women affected by PND without adequate treatment systematically reported more severe symptoms in their children than those being treated, resulting in overestimation of the effects of SSRIs. Although the degree of reporting bias associated with maternal depression has been found to be small [56], replication of our findings using data from different reporters are needed. In addition, the current study used self-report medication history to identify treated and non-treated mother-child PND dyads. Although recall bias may be a potential concern, the concordance between self-reports and records from the national prescription database for SSRI use during pregnancy is high in MoBa [57]. Second, SSRI dosage and antidepressant levels in infants were not available in MoBa. Although established data from clinical studies has previously shown that in general SSRI levels are very low or undetectable in breastfed infants [21], it would be ideal to include the information as a covariate to control for exposure level. Another limitation regarding data availability is that it remains unknown whether women in MoBa received non-pharmacological intervention alongside (or instead of) SSRIs. The effects associated with SSRI treatment may be exaggerated if the women simultaneously received other forms of treatment for PND or weakened if women in the ‘non-treated’ dyad presented with better outcomes due to non-pharmacological interventions. Finally, the prevalence of PND was 3.7% in our sample, much lower than the widely reported 10-15% [58]. This may be due to the conservative definition of PND we used in the current study

(self-reported experience of postnatal mental health problem & above threshold EPDS scores). Our conservative criteria were intended to select women experiencing severe PND symptoms (who might be considered eligible for diagnosis and treatment) and to minimise misclassification and false positive results. However, the low prevalence may also result from self-selection bias that healthier women were over-represented in MoBa compared with the total birthing population in Norway [59]. In addition, as seen in other longitudinal population-based cohorts, MoBa also suffers from non-random attrition [60, 61]. It has been reported that traits associated with lower socioeconomic status were predictive of study drop-out at 8 years after childbirth in the MoBa cohort [62]. Therefore, it is possible that women with more severe depression had higher drop-out rates and were missing from our analyses. Future research with linkage to health registry databases may provide a solution that avoids selection bias and enables comparison among all cohort members.

Conclusion

In this longitudinal study we aimed to increase understanding of the long-term outcomes associated with SSRI treatment of mother-child dyads affected by PND. Maternal postnatal depression was associated with poorer maternal and child mental health outcomes and child developmental outcomes up to postpartum year 5. However, the associations between PND and some unfavourable outcomes were attenuated by SSRI treatment. We did not find evidence that postnatal SSRI exposure increased the risk of child's emotional and behavioral problems or delayed motor and language development. While our findings need to be replicated, we believe that they add important information regarding long-term outcomes associated with SSRI use for postnatal maternal depression for clinicians and affected families.

Acknowledgements

The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this on-going cohort study. The positions of CYL and TAM are supported by a Wellcome Trust Senior Research Fellowship awarded to TAM [220382/Z/20/Z]. EY was supported by the Norwegian Research Council (262177 and 288083). **For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission**

Disclosure

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Regional Committee for Medical Research Ethics. Informed consent was obtained from all individual participants included in the study.

All authors declare no conflict of interest.

Reference

1. Woody, C.A., et al., *A systematic review and meta-regression of the prevalence and incidence of perinatal depression.* J Affect Disord, 2017. **219**: p. 86-92.
2. Disease, G.B.D., I. Injury, and C. Prevalence, *Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.* Lancet, 2018. **392**(10159): p. 1789-1858.
3. American Psychiatric Association, D. and A.P. Association, *Diagnostic and statistical manual of mental disorders: DSM-5*. Vol. 5. 2013: American psychiatric association Washington, DC.
4. Vliegen, N., et al., *Hospitalization-based treatment for postpartum depressed mothers and their babies: rationale, principles, and preliminary follow-up data.* Psychiatry, 2013. **76**(2): p. 150-68.
5. Prenoveau, J., et al., *Postpartum GAD is a risk factor for postpartum MDD: the course and longitudinal relationships of postpartum GAD and MDD.* Depress Anxiety, 2013. **30**(6): p. 506-14.
6. Garthus-Niegel, S., et al., *The Impact of Postpartum Posttraumatic Stress and Depression Symptoms on Couples' Relationship Satisfaction: A Population-Based Prospective Study.* Front Psychol, 2018. **9**: p. 1728.
7. Faisal-Cury, A., K. Tabb, and A. Matijasevich, *Partner relationship quality predicts later postpartum depression independently of the chronicity of depressive symptoms.* Braz J Psychiatry, 2020. **43**(1): p. 12-21.
8. Mamun, A.A., et al., *Maternal depression and the quality of marital relationship: a 14-year prospective study.* J Womens Health (Larchmt), 2009. **18**(12): p. 2023-31.
9. Lancaster, C.A., et al., *Risk factors for depressive symptoms during pregnancy: a systematic review.* Am J Obstet Gynecol, 2010. **202**(1): p. 5-14.
10. Wolford, E., et al., *Maternal depressive symptoms during and after pregnancy are associated with attention-deficit/hyperactivity disorder symptoms in their 3- to 6-year-old children.* PLoS One, 2017. **12**(12): p. e0190248.
11. Murray, L., et al., *The effects of maternal postnatal depression and child sex on academic performance at age 16 years: a developmental approach.* J Child Psychol Psychiatry, 2010. **51**(10): p. 1150-9.
12. Netsi, E., et al., *Association of Persistent and Severe Postnatal Depression With Child Outcomes.* JAMA Psychiatry, 2018. **75**(3): p. 247-253.
13. Park, M., et al., *Maternal depression trajectories from pregnancy to 3 years postpartum are associated with children's behavior and executive functions at 3 and 6 years.* Arch Womens Ment Health, 2018. **21**(3): p. 353-363.
14. Brown, J.V., et al., *Antidepressant treatment for postnatal depression.* Cochrane Database of Systematic Reviews, 2021(2).
15. McAllister-Williams, R.H., et al., *British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.* J Psychopharmacol, 2017. **31**(5): p. 519-552.
16. Lupattelli, A., et al., *Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Aged Children.* J Am Acad Child Adolesc Psychiatry, 2018. **57**(3): p. 200-208.

17. Grove, K., A.J. Lewis, and M. Galbally, *Prenatal Antidepressant Exposure and Child Motor Development: A Meta-analysis.* Pediatrics, 2018. **142**(1).
18. Brown, A.S., et al., *Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.* JAMA Psychiatry, 2016. **73**(11): p. 1163-1170.
19. Brandlistuen, R.E., et al., *Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings.* Int J Epidemiol, 2015. **44**(4): p. 1397-407.
20. Orsolini, L. and C. Bellantuono, *Serotonin reuptake inhibitors and breastfeeding: a systematic review*. Hum Psychopharmacol, 2015. **30**(1): p. 4-20.
21. Berle, J.O. and O. Spigset, *Antidepressant Use During Breastfeeding.* Curr Womens Health Rev, 2011. **7**(1): p. 28-34.
22. Turner, K.M., et al., *Women's views and experiences of antidepressants as a treatment for postnatal depression: a qualitative study.* Fam Pract, 2008. **25**(6): p. 450-5.
23. Pearlstein, T.B., et al., *Patient choice of treatment for postpartum depression: a pilot study.* Arch Womens Ment Health, 2006. **9**(6): p. 303-8.
24. Wajid, A., et al., *Psychosocial factors associated with trajectories of maternal psychological distress over a 10-year period from the first year postpartum: An Australian population-based study.* Journal of affective disorders, 2020. **263**: p. 31-38.
25. Kronenfeld, N., et al., *Use of Psychotropic Medications in Breastfeeding Women.* Birth Defects Res, 2017. **109**(12): p. 957-997.
26. Slomian, J., et al., *Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes.* Womens Health (Lond), 2019. **15**: p. 1745506519844044.
27. Magnus, P., et al., *Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa).* Int J Epidemiol, 2016. **45**(2): p. 382-8.
28. Cox, J.L., J.M. Holden, and R. Sagovsky, *Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale.* Br J Psychiatry, 1987. **150**: p. 782-6.
29. NICE and N.I.f.H.a.C. Excellence, *Treating specific mental health problems in pregnancy and the postnatal period*, in *Intervention for depression*. 2014, National Institute for Health and Care Excellence: London.
30. Hesbacher, P.T., et al., *Psychiatric illness in family practice.* J Clin Psychiatry, 1980. **41**(1): p. 6-10.
31. Tambs, K. and E. Røysamb, *Selection of questions to short-form versions of original psychometric instruments in MoBa.* Norsk Epidemiologi, 2014. **24**(1-2).
32. Røysamb, E., J. Vittersø, and K. Tambs, *The Relationship Satisfaction scale – Psychometric properties.* Norsk Epidemiologi, 2014. **24**(1-2).
33. Dyrdal, G.M., et al., *Can a Happy Relationship Predict a Happy Life? A Population-Based Study of Maternal Well-Being During the Life Transition of Pregnancy, Infancy, and Toddlerhood.* J Happiness Stud, 2011. **12**: p. 947-962.
34. Achenbach, T.M., *Manual for the Child Behaviour Checklist/2-3 and 1992 Profile*. 1992, Burlington: VT: University of Vermont Department of Psychiatry.
35. Conners, C.K., et al., *The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity.* J Abnorm Child Psychol, 1998. **26**(4): p. 257-68.
36. Squires, J., D. Bricker, and E. Twombly, *The ASQ User's Guide (2nd edition)*. 1999, Baltimore: Paul H. Brookes Publishing Co.
37. Richter, J. and H. Janson, *A validation study of the Norwegian version of the Ages and Stages Questionnaires.* Acta Paediatr, 2007. **96**(5): p. 748-52.

38. Team, R.C., *R: A Language and Environment for Statistical Computing*. 2020, R Foundation for Statistical Computing: Vienna, Austria.
39. Benjamini, Y. and D. Yekutieli, *The control of the false discovery rate in multiple testing under dependency.* Annals of statistics, 2001: p. 1165-1188.
40. Butterworth, P., S.C. Olesen, and L.S. Leach, *Socioeconomic differences in antidepressant use in the PATH Through Life Study: evidence of health inequalities, prescribing bias, or an effective social safety net?* J Affect Disord, 2013. **149**(1-3): p. 75-83.
41. Robertson, E., et al., *Antenatal risk factors for postpartum depression: a synthesis of recent literature*. Gen Hosp Psychiatry, 2004. **26**(4): p. 289-95.
42. Proust-Lima, C., V. Philipps, and B. Liquet, *Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm.* Journal of Statistical Software, 2017. **78**: p. 1-56.
43. Di Florio, A., et al., *Perinatal episodes across the mood disorder spectrum.* JAMA Psychiatry, 2013. **70**(2): p. 168-75.
44. Chew-Graham, C.A., et al., *Disclosure of symptoms of postnatal depression, the perspectives of health professionals and women: a qualitative study*. BMC Fam Pract, 2009. **10**: p. 7.
45. Bilszta, J., et al., *A Qualitative Study of Health Professionals Involved in the Care and Treatment of Women with Postnatal Emotional Distress.* International Journal of Mental Health Promotion, 2010. **12**(3): p. 5-13.
46. Megnin-Viggars, O., et al., *Experience of care for mental health problems in the antenatal or postnatal period for women in the UK: a systematic review and meta-synthesis of qualitative research.* Arch Womens Ment Health, 2015. **18**(6): p. 745-59.
47. Polte, C., et al., *Impact of Maternal Perinatal Anxiety on Social-Emotional Development of 2-Year-Olds, A Prospective Study of Norwegian Mothers and Their Offspring : The Impact of Perinatal Anxiety on Child Development.* Matern Child Health J, 2019. **23**(3): p. 386-396.
48. Ahmadzadeh, Y.I., et al., *Systematic Review and Meta-analysis of Genetically Informed Research: Associations Between Parent Anxiety and Offspring Internalizing Problems*. J Am Acad Child Adolesc Psychiatry, 2021. **60**(7): p. 823-840.
49. Figueiredo, B., et al., *Couples' relationship affects mothers' and fathers' anxiety and depression trajectories over the transition to parenthood.* J Affect Disord, 2018. **238**: p. 204-212.
50. Rosand, G.M., et al., *Partner relationship satisfaction and maternal emotional distress in early pregnancy.* BMC Public Health, 2011. **11**: p. 161.
51. Walker, A.L., et al., *The Long-Term Impact of Maternal Anxiety and Depression Postpartum and in Early Childhood on Child and Paternal Mental Health at 11-12 Years Follow-Up.* Front Psychiatry, 2020. **11**: p. 562237.
52. Rajyaguru, P., et al., *Maternal and paternal depression and child mental health trajectories: evidence from the Avon Longitudinal Study of Parents and Children.* BJPsych Open, 2021. **7**(5): p. e166.
53. Ford, E., et al., *Diagnosis and management of perinatal depression and anxiety in general practice: a meta-synthesis of qualitative studies.* Br J Gen Pract, 2017. **67**(661): p. e538-e546.
54. Stein, A., et al., *Mitigating the effect of persistent postnatal depression on child outcomes through an intervention to treat depression and improve parenting: a randomised controlled trial.* The Lancet Psychiatry, 2018. **5**(2): p. 134-144.

55. Liskola, K., et al., *The effects of maternal depression on their perception of emotional and behavioral problems of their internationally adopted children.* Child Adolesc Psychiatry Ment Health, 2021. **15**(1): p. 41.
56. van der Toorn, S.L., et al., *Maternal depressive symptoms, and not anxiety symptoms, are associated with positive mother-child reporting discrepancies of internalizing problems in children: a report on the TRAILS study.* Eur Child Adolesc Psychiatry, 2010. **19**(4): p. 379-88.
57. Skurtveit, S., et al., *Prenatal exposure to antidepressants and language competence at age three: results from a large population-based pregnancy cohort in Norway.* BJOG, 2014. **121**(13): p. 1621-31.
58. O'hara, M.W. and A.M. Swain, *Rates and risk of postpartum depression—a meta-analysis.* International review of psychiatry, 1996. **8**(1): p. 37-54.
59. Nilsen, R.M., et al., *Self-selection and bias in a large prospective pregnancy cohort in Norway.* Paediatr Perinat Epidemiol, 2009. **23**(6): p. 597-608.
60. Greene, N., et al., *Estimating bias from loss to follow-up in the Danish National Birth Cohort.* Epidemiology, 2011. **22**(6): p. 815-22.
61. Boyd, A., et al., *Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children.* Int J Epidemiol, 2013. **42**(1): p. 111-27.
62. Vejrup, K., P. Magnus, and M. Magnus, *Lost to follow-up in the Norwegian mother, father and child cohort study*. Paediatr Perinat Epidemiol, 2022. **36**(2): p. 300-309.

Table 1.1, Prenatal and antenatal maternal and child characteristics of non PND and PND dyads

	Non PND n= 52516	PND N=2060		
	mean (sd)	mean (sd)	OR	Adj OR (95% CI)
Maternal prenatal characteristics				
Maternal age	30.78 (18.58)	29.93 (4.79)	0.97 (0.96, 0.98) ***	1.00 (0.99, 1.00)
Parity	0.74 (0.85)	0.68 (0.86)	0.92 (0.87, 0.97) ***	0.91 (0.86, 0.97) ***
Maternal education				
Ranking (scale 1-6)	4.76 (1.15)	4.46 (1.33)	0.78 (0.75, 0.81) ***	0.94 (0.89, 1.00)
Maternal Income				
Ranking (scale 1-7)	4.23 (1.32)	3.83 (1.39)	0.74 (0.70, 0.77) ***	0.87 (0.83, 0.92) ***
Antenatal alcohol exposure				
Ever used in pregnancy, N (%)	36721(69.9)	1343 (65.2)	1.24 (1.13, 1.36) ***	1.22 (1.10, 1.35) ***
Antenatal tobacco exposure				

Ever used in pregnancy, N (%)	2702 (5.1)	1880 (91.3)	1.77 (1.50, 2.06) ***	0.94 (0.77, 1.13)
Lifetime depression diagnosis, N (%)	2650 (5)	676 (32.8)	9.19 (8.31, 10.15) ***	4.70 (4.19, 5.27) ***
Antenatal maternal mental health (Gestational week 30)				
depression	5.11 (1.47)	7.02 (2.63)	2.01 (1.95, 2.07) ***	1.45 (1.38, 1.52) ***
anxiety	4.72 (1.24)	6.39 (2.45)	1.94 (1.89, 2.00) ***	1.35 (1.29, 1.41) ***
Postnatal depression				
EPDS	2.72 (2.88)	8.61 (3.47)	-	-
Child characteristics				
Birth weight (kg)	3.59 (0.55)	3.55 (0.59)	0.93 (0.89, 0.98)	0.95 (0.90, 1.01)
Gestational age (weeks)	39.75 (2.29)	39.69 (2.22)	0.98 (0.93, 1.02)	1.05 (0.99, 1.11)

a. Adjusted multiple logistic regression controlling for all the prenatal and antenatal factors to identify predictors for PND: reference group is non-PND dyads
b. Reported p value were adjusted for multiple comparison (FDR< 0.5), ***p<0.001, ** p<0.01, *p<0.05
c. Birth weight and gestational age of the child were not different between the two groups

Table 1.2, Prenatal and antenatal maternal and child characteristics of non-treated PND and treated PND

	Non-treated PND dyad n=1877	Treated PND dyad n=183	Treated Vs. Non- treated	
	mean (sd)	mean (sd)	OR (95% CI)	Adj OR (95% CI)
Maternal prenatal characteristics				
Maternal age	29.95 (4.76)	29.80 (5.06)	0.99 (0.96, 1.03)	1.00 (0.96, 1.04)
Parity	0.68 (0.87)	0.66 (0.82)	0.97 (0.81,1.15)	0.96 (0.77, 1.18)
Maternal education				
Ranking (scale 1-6)	4.49 (1.32)	4.19 (1.43)	0.82 (0.71,0.94) *	0.84 (0.71, 1.00)
Maternal Income				
Ranking (scale 1-7)	3.84 (1.40)	3.74 (1.38)	0.93 (0.80, 1.08)	1.10 (0.91, 1.32)
Antenatal alcohol exposure				
ever used in pregnancy, N (%)	659 (35.1)	58 (31.7)	0.86 (0.62, 1.18)	0.87 (0.62,1.22)
Antenatal tobacco exposure				
Ever used in pregnancy, N (%)	160 (8.5)	20 (10.9)	1.32 (0.78, 2.11)	1.05 (0.59, 1.77)
Lifetime depression diagnosis, N (%)	566 (30.2)	110 (60.1)	3.49 (2.56, 4.78) ***	3.08 (2.20, 4.32) ***

Antenatal maternal mental health (Gestational week 30)				
Depression	6.97 (2.60)	7.57 (2.87)	1.14 (1.04, 1.24) *	0.95 (0.82, 1.09)
Anxiety	6.31 (2.41)	7.09 (2.73)	1.18 (1.09, 1.27) ***	1.14 (1.00, 1.29)
Postnatal depression (Postnatal month 6)				
EPDS	8.59 (3.46)	8.80 (3.60)	-	-
Child characteristics				
Birth weight (kg)	3.56 (0.59)	3.55 (0.57)	0.99 (0.85, 1.16)	1.08 (0.89, 1.31)
Gestational age (weeks)	39.72 (2.24)	39.47 (2.09)	0.89 (0.75, 1.05)	0.90 (0.72, 1.11)

a. Adjusted multiple logistic regression controlling for all the prenatal and antenatal factors to identify predictors for SSRI treatment: reference group is non-treated PND dyads
b. Reported p value were adjusted for multiple comparison (FDR< 0.5), ***p<0.001, ** p<0.01, *p<0.05
c. Postnatal month 6 EPDS, birth weight and gestational age of the child were not different between the two groups

Table 2 Descriptive of maternal and child outcomes and the association between PND, SSRI treatment and the study outcomes

			Model without interaction		Model with interaction	
	non-PND dyads n= 52516 mean (sd)	PND dyads n=2060 mean (sd)	Crude ß (CI)	Adjusted ß (CI)	PND Adjusted ß (CI)	PND*SSRI ß (CI)
Maternal outcomes						
Maternal depression, mean (SD)						
postpartum year 1.5	5.31 (1.69)	7.79 (2.85)	1.33 (1.28, 1.38) ***	0.80 (0.76, 0.85) ***	0.71 (0.66, 0.75) ***	-0.36 (-0.50, -0.21) ***
postpartum year 3	5.27 (1.79)	7.51 (2.94)	1.14 (1.09, 1.19) ***	0.64 (0.59, 0.69) ***	0.55 (0.50, 0.61) ***	-0.11 (-0.28, 0.07)
postpartum year 5	4.98 (1.57)	6.62 (2.67)	0.96 (0.90, 1.02) ***	0.53 (0.47, 0.59) ***	0.46 (0.40, 0.53) ***	-0.40 (-0.59, -0.20) ***
Maternal anxiety,						

mean (SD)						
postpartum year 1.5	4.70 (1.23)	6.62 (2.51)	1.36 (1.31, 1.41) ***	0.84 (0.80, 0.89) ***	0.69 (0.65, 0.74) ***	-0.17 (-0.32, -0.03) *
postpartum year 3	4.71 (1.32)	6.47 (2.46)	1.18 (1.12, 1.23) ***	0.69 (0.64, 0.74) ***	0.56 (0.51, 0.62) ***	0.17 (0.00, 0.34)
postpartum year 5	4.56 (1.15)	5.79 (2.17)	0.97 (0.91, 1.03) ***	0.55 (0.49, 0.61) ***	0.43 (0.37, 0.50) ***	-0.11 (-0.31, 0.08)
Maternal report of relationship satisfaction						
postpartum month 6	53.19 (6.69)	48.03 (9.39)	-0.71 (-0.75, -0.66) ***	-0.45 (-0.49, -0.41) ***	-0.42 (-0.46, -0.37) ***	0.49 (0.35, 0.63) ***
postpartum year 1.5	52.29 (7.40)	47.47 (9.94)	-0.60 (-0.65, -0.55) ***	-0.35 (-0.40, -0.30) ***	-0.35 (-0.40, -0.30) ***	0.41 (0.25, 0.57) ***
postpartum year 3	50.66 (8.56)	45.18 (10.92)	-0.60 (-0.66, -0.54) ***	-0.38 (-0.44, -0.32) ***	-0.37 (-0.43, -0.31) ***	0.25 (0.06, 0.44) *

Child outcomes						
Internalising problems						
1.5y	3.85 (0.88)	4.04 (1.00)	0.20 (0.16, 0.25) ***	0.06 (0.00, 0.11)	0.06 (0.01, 0.11)	-0.04 (-0.20, 0.11)
3 y	3.70 (0.90)	3.97 (1.09)	0.28 (0.23, 0.34) ***	0.10 (0.05, 0.16) ***	0.11 (0.05, 0.17) ***	-0.12 (-0.31 0.06)
5 y	3.53 (0.85)	3.97 (1.09)	0.32 (0.25, 0.38) ***	0.15 (0.09, 0.22) ***	0.13 (0.06, 0.20) ***	-0.18 (-0.39 0.03)
Externalising problems						
1.5y	11.86 (2.21)	12.53 (2.41)	0.29 (0.24, 0.34) ***	0.12 (0.07, 0.17) ***	0.14 (0.09, 0.19) ***	-0.21 (-0.37, -0.05) *
3 y	11.80 (2.38)	12.59 (2.68)	0.32 (0.27, 0.38) ***	0.15 (0.09, 0.21) ***	0.17 (0.11, 0.22) ***	-0.17 (-0.36, 0.02)
5 y	10.42 (2.22)	11.20 (2.66)	0.34 (0.27, 0.40)	0.15 (0.09, 0.22)	0.15 (0.08, 0.22) ***	-0.32 (-0.53, -0.11)

			***	***		*
ADHD symptoms 5y	16.31 (4.47)	18.36 (5.90)	0.44 (0.38, 0.50) ***	0.22 (0.16, 0.29) ***	0.22 (0.15, 0.28) ***	-0.37 (-0.57, -0.16) ***
Motor development						
1.5y	23.04 (1.57)	22.72 (1.94)	-0.19 (-0.24, -0.15) ***	-0.13 (-0.18, -0.08) ***	-0.11 (-0.17, -0.06) ***	-0.19 (-0.35, -0.03)
3y	21.65 (2.69)	21.29 (2.83)	-0.14 (-0.19, -0.08) ***	-0.09 (-0.14, -0.03) *	-0.08 (-0.14, -0.02) *	-0.08 (-0.27, 0.10)
Language development						
1.5y	13.51 (1.76)	13.23 (1.99)	-0.16 (-0.21, -0.11) ***	-0.10 (-0.14, -0.04) ***	-0.09 (-0.14, -0.04) ***	-0.09 (-0.25, 0.07)
3y	14.48 (1.76)	14.31 (1.99)	-0.18 (-0.23, -0.12) ***	-0.09 (-0.14, -0.04) *	-0.08 (-0.13, -0.02) *	-0.07 (-0.26, 0.11)

a. Crude ß, standardised regression coefficient
b. Adjusted ß, standardised regression coefficient adjusted for covariates
c. Covariate for maternal outcomes include maternal age, education, income, parity, maternal lifetime depression diagnosis, depression and anxiety at gestational week 30 and propensity score for receiving SSRI treatment

d. Covariates for child outcomes include child sex, birthweight, maternal age, education, income, parity, maternal lifetime depression diagnosis, depression and anxiety at gestational week 30 and propensity score for receiving SSRI treatment
e. Interaction model was the extension of multivariable regression with added PND*SSRI moderation terms
f. Reported p value were adjusted for multiple comparison (FDR 5%), ***$p<0.001$, ** $p<0.01$, *$p<0.05$